CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients With Incurable Pancreatic Cancer.
Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients With Incurable Pancreatic Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
数据提示，使用 ZAK 细胞进行 AIT 联合化疗是安全可行的，并可能有效延长不可治愈胰腺癌患者的生存期。基线淋巴细胞百分比可能是预测 ZAK 细胞 AIT 生存获益的良好生物标志物。
采用自体唑来膦酸激活杀伤（ZAK）细胞的过继免疫治疗（AIT）已被用于开发一种新的癌症治疗模式。本研究分析了来自不可治愈的胰腺癌的数据系列。
患者接受AIT治疗，每3至4周静脉注射ZAK细胞，并结合标准化疗，同时考察了可能的临床获益。
75例患者接受了治疗。所有患者的中位总生存期（OS）为6.7个月，治疗5次或以上的患者为13.1个月；当分析中纳入既往单纯化疗治疗期时，这两组分别增至14.6个月和18.3个月。疾病控制率为58.5%。多因素回归分析显示，生存期与白细胞计数中淋巴细胞百分比的基线值呈显著正相关（p=0.031）。
Patients were treated with AIT using intravenous administration of ZAK cells every 3 to 4 weeks in combination with standard chemotherapy and possible clinical benefits were examined.
Seventy-five patients were treated. A median overall survival (OS) time of 6.7 months was achieved for all patients and 13.1 months for those treated 5 times or more, that increased to 14.6 and 18.3 months, respectively, when the previous treatment period of chemotherapy alone was included in the analysis. The disease control rate was 58.5 %. Multivariate regression analysis showed a significant positive correlation between the survival and baseline value of lymphocyte percentage in white blood cell counts (p=0.031).
The data suggest that AIT using ZAK cells in combination with chemotherapy is safe and feasible and may be effective in prolonging survival for patients with incurable pancreatic cancer. The lymphocyte percentage at baseline may be a good biomarker for predicting the survival benefit of ZAK cell AIT.
MEMBER ACCOUNT
登录成功会直接打开下一页。
